• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

熊去氧胆酸治疗原发性胆汁性肝硬化患者。

Ursodeoxycholic acid treatment in a patient with primary biliary cirrhosis.

作者信息

Wouters R S, Bos L P, Engels L G

机构信息

Department of Gastroenterology, Maaslandziekenhuis, Sittard.

出版信息

Neth J Med. 1990 Aug;37(1-2):21-3.

PMID:2215828
Abstract

A women with stage I-II primary biliary cirrhosis was treated with ursodeoxycholic acid (UDCA). During UDCA treatment a notable improvement in biochemical liver profile was achieved. Liver histology did not deteriorate after one year UDCA. UDCA offers a promising non-toxic alternative in the treatment of PBC.

摘要

一名患有I-II期原发性胆汁性肝硬化的女性接受了熊去氧胆酸(UDCA)治疗。在UDCA治疗期间,肝脏生化指标有显著改善。UDCA治疗一年后肝脏组织学并未恶化。UDCA为原发性胆汁性肝硬化的治疗提供了一种有前景的无毒替代方案。

相似文献

1
Ursodeoxycholic acid treatment in a patient with primary biliary cirrhosis.熊去氧胆酸治疗原发性胆汁性肝硬化患者。
Neth J Med. 1990 Aug;37(1-2):21-3.
2
Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis.原发性胆汁性肝硬化患者长期服用熊去氧胆酸后胆汁酶水平及瘙痒症状的改善
Am J Gastroenterol. 1990 Jan;85(1):15-23.
3
A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group.一项比较秋水仙碱与熊去氧胆酸联合用药和熊去氧胆酸治疗原发性胆汁性肝硬化的随机试验。熊去氧胆酸治疗原发性胆汁性肝硬化研究组。
Hepatology. 1996 Nov;24(5):1098-103. doi: 10.1002/hep.510240520.
4
Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.长期服用熊去氧胆酸可延缓原发性胆汁性肝硬化的组织学进展。
Hepatology. 1999 Mar;29(3):644-7. doi: 10.1002/hep.510290301.
5
Ursodeoxycholic acid treatment in primary biliary cirrhosis with the emphasis on late stage disease.熊去氧胆酸治疗原发性胆汁性肝硬化,重点关注晚期疾病。
Neth J Med. 1992 Aug;41(1-2):11-6.
6
Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.对熊去氧胆酸有生化反应的原发性胆汁性肝硬化患者预后改善。
Gastroenterology. 2009 Apr;136(4):1281-7. doi: 10.1053/j.gastro.2009.01.003. Epub 2009 Jan 14.
7
Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy.甲氨蝶呤用于对熊去氧胆酸治疗生化反应不完全的原发性胆汁性肝硬化患者进行症状性治疗。
Aliment Pharmacol Ther. 2006 Sep 1;24(5):813-20. doi: 10.1111/j.1365-2036.2006.03048.x.
8
Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.熊去氧胆酸治疗肝移植后复发性原发性胆汁性肝硬化的长期生存情况及影响
Liver Transpl. 2007 Sep;13(9):1236-45. doi: 10.1002/lt.21124.
9
Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.熊去氧胆酸治疗原发性胆汁性肝硬化应答不完全后应用苯扎贝特治疗。
J Clin Gastroenterol. 2010 May-Jun;44(5):371-3. doi: 10.1097/MCG.0b013e3181c115b3.
10
Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.原发性胆汁性肝硬化-自身免疫性肝炎重叠综合征:临床特征及对治疗的反应
Hepatology. 1998 Aug;28(2):296-301. doi: 10.1002/hep.510280203.